查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067509

癌症生物標記市場規模、佔有率和趨勢分析報告：按類型、生物分子、應用、技術、地區和細分市場預測（2026-2033 年）

Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type, By Biomolecule, By Application, By Technology, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

癌症生物標記市場概述

2025年全球癌症生物標記市場價值為269.2億美元，預計2033年將達到653億美元。

預計從2026年到2033年，該產業將以11.82%的複合年成長率成長。這一成長歸因於癌症患者數量的增加以及對早期診斷和個人化治療的日益重視。

基因組學、蛋白質組學、次世代定序和分子診斷技術的進步正在加速癌症生物標記檢測市場的創新。醫院和實驗室正在採用基於生物標記的檢測方法來改善治療效果。政府的支持和不斷擴大的研究活動進一步推動了市場成長，而對標靶治療的需求也持續在全球創造新的機會。

癌症仍然是21世紀全球面臨的健康挑戰和主要死因之一。 2025年9月發表在《柳葉刀》上的一項名為「2023年全球疾病負擔（GBD）」的調查評估了1990年至2023年間204個國家和地區47種癌症的負擔，並預測了2050年的情況。據估計，2023年癌症將成為全球第二大死因，僅次於心血管疾病，預計2050年，癌症相關死亡人數將超過1,800萬人。此外，健康指標與評估研究所（IHME）於2025年9月發布的估計數據顯示，全球整體將新增1850萬例癌症病例，並有超過1040萬人死於癌症，導致約2.71億失能調整後存活年（DALYs）損失。其中，近60%的癌症病例和超過60%的癌症死亡病例發生在低收入和中等收入國家，凸顯了疾病負擔和醫療保健服務取得的巨大差異。 2023年，肺癌被認定為癌症相關死亡的首要原因，其次是大腸癌，位居第二。需要持續照護的患者數量不斷增加，預計將加速生物標記技術的應用，從而推動癌症生物標記市場的成長。

該研究透過支持早期診斷、標靶治療選擇和疾病監測等創新技術的開發，在推動癌症生物標記市場發展方面發揮著至關重要的作用。政府投入的不斷增加持續加速腫瘤學研究和生物標記發現。美國國家癌症研究所 (NCI) 仍然是主要貢獻者，支援其位於馬裡蘭州總部、各學術機構以及全球合作機構所進行的研究活動。根據 NCI 於 2025 年 7 月發布的數據，該研究所的總經費為 72 億美元，其中 43.3% 的承諾預算用於研究計畫津貼。這些投資顯著地推進了基於生物標記的診斷、精準腫瘤學、免疫腫瘤學和液態生物檢體技術的發展，從而支持癌症生物標記市場的創新和成長。

技術進步正在透過提升精準腫瘤學、早期檢測和個人化治療方案，改變癌症生物標記市場。隨著基於生物標記的診斷和標靶治療的整合不斷推進，臨床應用也持續擴展。例如，2025年1月，羅氏的伴隨診斷試劑PATHWAY HER2 (4B5)獲得FDA批准，用於識別HER2表達極低的轉移性乳癌患者，這凸顯了基於生物標記的患者分層技術的進步。液態生物檢體技術的持續創新也在加速市場成長。 2024年6月，Guardant Health擴展了其液態生物檢體試劑Guardant360的臨床應用範圍，使其能夠進行全面的基因組分析和即時腫瘤監測。此外，2024年8月，Illumina改進了其腫瘤定序平台，實現了高通量基因組分析，並增強了基於生物標記的精準腫瘤學在多種癌症類型中的應用。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 癌症生物標記市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：癌症生物標記市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 乳癌
  • 攝護腺癌
  • 結腸癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 其他

第5章：癌症生物標記市場：生物分子業務分析

  • 2025年及2033年生物分子市場佔有率
  • 生物分子特異性市場規模、預測與趨勢分析（2021-2033年）
  • 基因生物標記
  • 表觀遺傳生物標記
  • 代謝生物標記
  • 蛋白質體學生物標記

第6章：癌症生物標記市場：按應用領域分類的業務分析

  • 按應用領域分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按應用領域分類，2021-2033年
  • 藥物發現與開發
  • 診斷
  • 個人化醫療

第7章：癌症生物標記市場：按技術分類的商業分析

  • 按技術分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按技術分類，2021-2033 年
  • 基於聚合酵素鏈鎖反應（PCR）的技術
  • 基於次世代定序（NGS）的技術
  • 基於免疫檢測測定的技術
  • 原位雜合反應（ISH）和細胞遺傳學技術
  • 基於質譜的技術
  • 基於醫學影像的生物標記技術

第8章：癌症生物標記市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co. Inc.
    • Hologic, Inc.
    • Sino Biological Inc.
Product Code: GVR-1-68038-862-6

Cancer Biomarkers Market Summary

The global cancer biomarkers market size was valued at USD 26.92 billion in 2025 and is projected to reach USD 65.30 billion by 2033, growing at a CAGR of 11.82% from 2026 to 2033. The growth is attributed to rising cancer cases and the increasing focus on early diagnosis and personalized treatment.

Advancements in genomics, proteomics, next-generation sequencing, and molecular diagnostic technologies are accelerating innovation in the cancer biomarker testing market. Hospitals and labs are adopting biomarker-based tests to improve outcomes. Supportive government initiatives and expanding research activities further boost growth, while demand for targeted therapies continues to create new opportunities worldwide.

Cancer remains one of the leading global health challenges and a major cause of mortality in the 21st century. According to a study published in The Lancet in September 2025, findings from the Global Burden of Disease (GBD) 2023 study indicate that cancer burden was assessed across 47 cancer types in 204 countries and territories from 1990 to 2023, with projections extending to 2050. Cancer was estimated to be the second leading cause of death globally in 2023, after cardiovascular diseases, with total cancer-related deaths expected to exceed 18 million by 2050. Furthermore, estimates published by the Institute for Health Metrics and Evaluation in September 2025 indicate that there were 18.5 million new cancer cases and more than 10.4 million deaths globally, contributing to approximately 271 million disability-adjusted life years (DALYs) lost. Of these, nearly 60% of cancer cases and over 60% of cancer deaths occurred in low- and middle-income countries, highlighting significant disparities in disease burden and access to care. Lung cancer and colorectal cancer were identified as the leading and second-leading causes of cancer-related deaths in 2023, respectively. The increasing number of patients requiring ongoing care is expected to accelerate the adoption of biomarker-based technologies, thereby supporting the growth of the cancer biomarkers market.

Research plays a critical role in advancing the cancer biomarkers market by supporting the development of innovative technologies for early diagnosis, targeted therapy selection, and disease monitoring. Increasing government funding continues to accelerate oncology research and biomarker discovery initiatives. The National Cancer Institute (NCI) remains a major contributor, supporting research activities across its headquarters in Maryland, academic institutions, and global collaborations. According to data published by the NCI in July 2025, the institute's funds totaled USD 7.2 billion, with 43.3% of the obligated budget allocated to Research Project Grants. These investments are significantly advancing biomarker-based diagnostics, precision oncology, immuno-oncology, and liquid biopsy technologies, thereby supporting innovation and growth in the cancer biomarkers market.

Technological advancements are transforming the cancer biomarkers market by improving precision oncology, early detection, and personalized treatment selection. Increasing integration of biomarker-driven diagnostics with targeted therapies continues to expand clinical applications. For instance, in January 2025, Roche received FDA approval for its PATHWAY HER2 (4B5) companion diagnostic test for identifying patients with HER2-ultralow metastatic breast cancer, highlighting advancements in biomarker-based patient stratification. Continuous innovation in liquid biopsy technologies is also accelerating market growth. In June 2024, Guardant Health expanded the clinical application of its Guardant360 liquid biopsy test for comprehensive genomic profiling and real-time tumor monitoring. Furthermore, in August 2024, Illumina advanced its oncology sequencing platforms, supporting high-throughput genomic profiling and strengthening biomarker-based precision oncology applications across multiple cancer types.

Global Cancer Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer biomarkers market report based on type, biomolecule, application, technology, and region

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Others
  • Biomolecule Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery and Development
  • Diagnostics
  • Personalized Medicine
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Polymerase Chain Reaction (PCR)-based Technologies
  • Next-Generation Sequencing (NGS)-based Technologies
  • Immunoassay-based Technologies
  • In Situ Hybridization (ISH) & Cytogenetic Technologies
  • Mass Spectrometry-based Technologies
  • Imaging-based Biomarker Technologies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Biomolecule
    • 1.2.3. Application
    • 1.2.4. Technology
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Biomarker Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Prevalence of Cancer
      • 3.2.1.2. Increasing Government Funding for Cancer Research
      • 3.2.1.3. Technological Advancement
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Reimbursement Policies
      • 3.2.2.2. Large Capital Investment
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Cancer Biomarker Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Breast Cancer
    • 4.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
  • 4.5. Prostate Cancer
    • 4.5.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 4.6. Colorectal Cancer
    • 4.6.1. Colorectal Cancer Market, 2021 - 2033 (USD Million)
  • 4.7. Cervical Cancer
    • 4.7.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
  • 4.8. Liver Cancer
    • 4.8.1. Liver Cancer Market, 2021 - 2033 (USD Million)
  • 4.9. Lung Cancer
    • 4.9.1. Lung Cancer Market, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Biomarker Market: Biomolecule Business Analysis

  • 5.1. Biomolecule Market Share, 2025 & 2033
  • 5.2. Biomolecule Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Biomolecule, 2021 to 2033 (USD Million)
  • 5.4. Genetic Biomarkers
    • 5.4.1. Genetic Biomarkers Market, 2021 - 2033 (USD Million)
  • 5.5. Epigenetic Biomarkers
    • 5.5.1. Epigenetic Biomarkers Market, 2021 - 2033 (USD Million)
  • 5.6. Metabolic Biomarkers
    • 5.6.1. Metabolic Biomarkers Market, 2021 - 2033 (USD Million)
  • 5.7. Proteomic Biomarkers
    • 5.7.1. Proteomic Biomarkers Market, 2021 - 2033 (USD Million)

Chapter 6. Cancer Biomarker Market: Application Business Analysis

  • 6.1. Application Market Share, 2025 & 2033
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Drug Discovery and Development
    • 6.4.1. Drug Discovery and Development Market, 2021 - 2033 (USD Million)
  • 6.5. Diagnostics
    • 6.5.1. Diagnostics Market, 2021 - 2033 (USD Million)
  • 6.6. Personalized Medicine
    • 6.6.1. Personalized Medicine Market, 2021 - 2033 (USD Million)

Chapter 7. Cancer Biomarker Market: Technology Business Analysis

  • 7.1. Technology Market Share, 2025 & 2033
  • 7.2. Technology Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 7.4. Polymerase Chain Reaction (PCR)-based Technologies
    • 7.4.1. Polymerase Chain Reaction (PCR)-based Technologies Market, 2021 - 2033 (USD Million)
  • 7.5. Next-Generation Sequencing (NGS)-based Technologies
    • 7.5.1. Next-Generation Sequencing (NGS)-based Technologies Market, 2021 - 2033 (USD Million)
  • 7.6. Immunoassay-based Technologies
    • 7.6.1. Immunoassay-based Technologies Market, 2021 - 2033 (USD Million)
  • 7.7. In Situ Hybridization (ISH) & Cytogenetic Technologies
    • 7.7.1. In Situ Hybridization (ISH) & Cytogenetic Technologies Market, 2021 - 2033 (USD Million)
  • 7.8. Mass Spectrometry-based Technologies
    • 7.8.1. Mass Spectrometry-based Technologies Market, 2021 - 2033 (USD Million)
  • 7.9. Imaging-based Biomarker Technologies
    • 7.9.1. Imaging-based Biomarker Technologies Market, 2021 - 2033 (USD Million)

Chapter 8. Cancer Biomarker Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Cancer Biomarker Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Abbott
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. QIAGEN
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Thermo Fisher Scientific Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Illumina, Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Agilent Technologies, Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Merck & Co. Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Hologic, Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Sino Biological Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global cancer biomarker market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 6 Global cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 7 Global cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 8 North America cancer biomarker market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 10 North America cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 11 North America cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 12 North America cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 15 U.S. cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 16 U.S. cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 17 Canada cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 18 Canada cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 19 Canada cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 20 Canada cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 21 Mexico cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 23 Mexico cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 24 Mexico cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 25 Europe cancer biomarker market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Europe cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 28 Europe cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 29 Europe cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 30 UK cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 31 UK cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 32 UK cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 33 UK cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 34 Germany cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 35 Germany cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 36 Germany cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 37 Germany cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 38 France cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 39 France cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 40 France cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 41 France cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 42 Italy cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 44 Italy cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 45 Italy cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 46 Spain cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 47 Spain cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 48 Spain cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 49 Spain cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 50 Norway cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Norway cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 52 Norway cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 53 Norway cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 54 Denmark cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Denmark cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 56 Denmark cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 57 Denmark cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 58 Sweden cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 59 Sweden cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 60 Sweden cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 61 Sweden cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific cancer biomarker market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 67 Japan cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 68 Japan cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 69 Japan cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 70 Japan cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 71 China cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 72 China cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 73 China cancer biomarker market, by Application, 2021 - 2033 (USD Million
  • Table 74 China cancer biomarker market, by Technology, 2021 - 2033 (USD Million))
  • Table 75 India cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 76 India cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 77 India cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 78 India cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 79 Australia cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 80 Australia cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 81 Australia cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 82 Australia cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 83 South Korea cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 84 South Korea cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 85 South Korea cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 86 South Korea cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 87 Thailand cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Thailand cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 89 Thailand cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 90 Thailand cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 91 Latin America cancer biomarker market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 94 Latin America cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 95 Latin America cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 96 Brazil cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 98 Brazil cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 99 Brazil cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 100 Argentina cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 102 Argentina cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 103 Argentina cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa cancer biomarker market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 109 South Africa cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 111 South Africa cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 112 South Africa cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 117 UAE cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 118 UAE cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 119 UAE cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 120 UAE cancer biomarker market, by Technology, 2021 - 2033 (USD Million)
  • Table 121 Kuwait cancer biomarker market, by Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait cancer biomarker market, by Biomolecule, 2021 - 2033 (USD Million)
  • Table 123 Kuwait cancer biomarker market, by Application, 2021 - 2033 (USD Million)
  • Table 124 Kuwait cancer biomarker market, by Technology, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cancer biomarker segmentation
  • Fig. 2 Cancer biomarker market segmentation
  • Fig. 3 Market research process
  • Fig. 4 Data triangulation techniques
  • Fig. 5 Primary research pattern
  • Fig. 6 Market research approaches
  • Fig. 7 Value chain based sizing & forecasting
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Market formulation & validation
  • Fig. 10 Market snapshot
  • Fig. 11 Type and biomolecule snapshot
  • Fig. 12 Technology and application snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Cancer biomarker market: Type outlook and key takeaways
  • Fig. 18 Cancer biomarker market: Type movement analysis
  • Fig. 19 Breast cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Prostate cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Colorectal cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Cervical cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Liver cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Lung cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Cancer biomarker market: Biomolecule outlook and key takeaways
  • Fig. 27 Cancer biomarker market: Biomolecule movement analysis
  • Fig. 28 Genetic biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Epigenetic biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Metabolic biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Proteomic biomarkers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Cancer biomarker market: Application outlook and key takeaways
  • Fig. 33 Cancer biomarker market: Application movement analysis
  • Fig. 34 Drug discovery & development cancer biomarker market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Diagnostics cancer biomarker market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Personalized medicine cancer biomarker market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Cancer biomarker market: Technology outlook and key takeaways
  • Fig. 38 Cancer biomarker market: Technology movement analysis
  • Fig. 39 PCR-based technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 NGS-based technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Immunoassay-based technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 ISH and cytogenetic technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Mass spectrometry-based technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Imaging-based biomarker technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Cancer biomarker revenue, by region, 2025 & 2033, (USD Million)
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 U.S. cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Canada cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Mexico cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Europe cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 UK cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Germany cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 France cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Spain cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Italy cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Sweden cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Denmark cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Norway cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific cancer biomarker estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Japan cancer biomarker estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 China cancer biomarker estimates and forecast, 2021 - 2033 (USD million)
  • Fig. 63 India cancer biomarker estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea cancer biomarker estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Australia cancer biomarker estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand cancer biomarker estimates and forecast, 2021 - 2033 (USD million)
  • Fig. 67 Latin America cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Argentina cancer biomarker estimates and forecasts, 2021 - 2033 (USD million)
  • Fig. 70 MEA cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa cancer biomarker estimates and forecasts, 2021 - 2033 (USD million)
  • Fig. 72 Saudi Arabia cancer biomarker estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 UAE cancer biomarker estimates and forecasts, 2021 - 2033 (USD million)
  • Fig. 74 Kuwait cancer biomarker estimates and forecasts, 2021 - 2033 (USD million)
  • Fig. 75 Key company categorization
  • Fig. 76 Company market share
  • Fig. 77 Strategy mapping